Today Stories
Breakthrough Expands its International Footprint, Entering the Burgeoning Amsterdam Life Science Community in Partnership with the Amsterdam University Medical Center
Anticipated to be One of the World's Most Advanced and Sustainable Laboratory Environments, Kavel F by Breakthrough Aims to Achieve Carbon Negative Operations and a BREEAM Outstanding Rating
AMSTERDAM, Sept. 21, 2023 /PRNewswire/ -- Breakthrough Properties, a premier global life sciences real estate developer, announced that it has reached an agreement with Neogene Therapeutics to develop its new European headquarters within the campus of the Amsterdam University Medical Center (Amsterdam UMC), one of Europe's leading medical institutions.
Neogene Therapeutics (Neogene), a wholly owned subsidiary of global biopharmaceutical c…
Solution seamlessly delivers proprietary technology, real world data and analytics, aligning to industry security and data privacy standards
Dublin, Ireland – 20 September 2023 – ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announces the release of its next generation Clinical Trial Tokenisation solution. The combination of ICON’s proprietary tokenisation engine, access to real-world data and advanced clinical analytics expertise, now delivered through a cohesive and seamless operational model, provides valuable, long-term insights on drug safety and efficacy, throughout the product development lifecycle.
ICON’s next generation proprietary Clinical Trial Tokenisation solution seamlessly integrates all the necessary components to…
Alexion, AstraZeneca Rare Disease, has completed a definitive purchase and licence agreement for a portfolio of preclinical rare disease gene therapy programmes and enabling technologies from Pfizer Inc. (Pfizer).
These new resources build on the combined capabilities of Alexion and AstraZeneca in genomic medicine, with the objective to develop new genetic therapies with improved safety and efficacy profiles. Additionally, several of the Pfizer employees associated with the portfolio will join Alexion as employees.
Financial considerations
Alexion has purchased and licenced the assets of Pfizer’s early-stage rare disease gene therapy portfolio for a total consideration of up to $1bn, plus tiered royalties on sales.
Notes
Alexion
Alexion, AstraZeneca Rare Disease, is the group within AstraZ…
Sanofi supporting vulnerable communities as part of commitment to social impact and fight against climate change
Paris, September 19, 2023 – As global leaders gather at the United Nations’ 78th General Assembly, Sanofi is delivering vital support to communities beset by climate turbulence and by unmet medical needs. These critical initiatives come as the global healthcare company confirms its commitment to positively impact society by tackling climate change and its consequences for human health.
Ramping up adaptation efforts and initiatives to address the impact of climate change on the health of vulnerable communities becomes increasingly critical. Through Foundation S, Sanofi’s philanthropic organization, the company is strengthening locally led adaptation and health resilience programs…
Brand and visual identity demonstrate the best of Johnson & Johnson’s care and humanity, while capturing the Company’s passion and determination to improve the health of people worldwide
New Brunswick, N.J., Sept. 14, 2023 – For more than 135 years, Johnson & Johnson (the “Company”) (NYSE: JNJ) has provided health care products and solutions to people worldwide. Now, with its exclusive focus on healthcare innovation and tackling the toughest health challenges, the Company is updating its brand and uniting both its medtech and pharmaceutical segments under the Johnson & Johnson brand name to demonstrate its collective power in healthcare.
The announcement marks the next era for Johnson & Johnson, which is leveraging its expertise in innovative medicine and medical tech…
Takeda’s Five New Partnerships Boost Total Global CSR Program Contributions to JPY 24.2 Billion (Approx. USD 167.5 million) Since Program Inception in 2016.
More Than 24,500 Takeda Employees Worldwide Participated in the Selection of the Five New Partnerships: Society for Family Health Rwanda, Relief International, Mercy Corps, University of Nairobi and Partners In Health.
With This New Cohort of Partnerships, Takeda’s Global CSR Program Expects to Reach 25.2 Million People in 92 Countries by 2028.
OSAKA, Japan and CAMBRIDGE, Massachusetts, September 13, 2023 – Takeda (TSE:4502/NYSE:TAK) today announced five new partnerships to its Global Corporate Social Responsibility (CSR) Program, which contribute to strengthening health systems in low- and middle-income countries. The new part…
UK site now set for clinical production of adeno-associated virus (AAV) vectors for gene therapy
Highly experienced team ready to support ATMP innovators at all stages
Offering comprehensive range of services from early process and analytical development through cGMP manufacturing for clinical trials
Stevenage, UK and Laupheim, Germany, September 13, 2023– Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, including advanced therapy medicinal products (ATMPs), today announced that it has received the cGMP Manufacturing Compliance Certificate, following the successful inspection by the UK Medicines & Healthcare Products Regulatory Agency (MHRA) at its UK site. The ATMP business was announced in early 2021 and th…
Collaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo expressed TCER® molecules
Companies to leverage Immatics' XPRESIDENT® target discovery platform and Moderna's mRNA technology for the development of novel cancer vaccines
Collaboration to include evaluation of Immatics' investigational IMA203 PRAME TCR-T in combination with Moderna's investigational PRAME mRNA cancer vaccine
Immatics to receive $120 million upfront cash payment plus research funding with the potential for additional milestone and royalty payments
CAMBRIDGE, MA and TUEBINGEN, GERMANY / ACCESSWIRE / September 11, 2023 / Moderna, Inc. (NASDAQ:MRNA, "Moderna") and Immatics N.V. (NASDAQ:IMTX, "Immatics"), a clinical-stage biopharmaceutical company active in the discovery and development of…
Awards distinguish innovations for delivering sustainability, efficiency and automation to researchers and therapy developers
WALTHAM, Mass.--(BUSINESS WIRE)-- Thermo Fisher Scientific Inc., the world leader in serving science, has been recognized by the R&D 100 Awards, honoring the top 100 revolutionary products in science and technology from around the world, for three unique innovations that aid researchers’ and scientists’ work in a variety of life science applications, including bioproduction and small-molecule analysis.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230908890343/en/
The three award-winning Thermo Fisher innovations include:
The Thermo Scientific™ DynaSpin™ Single-use Centrifuge, recognized in the Anal…
WALTHAM, Mass.--(BUSINESS WIRE)-- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and the National Minority Quality Forum (NMQF), an independent not-for-profit research and education organization, today announced a collaboration to help bring clinical research to historically underserved patient populations through NMQF’s Alliance for Representative Clinical Trials (ARC). The collaboration supports biopharmaceutical and biotech customers in meeting regulatory expectations to enroll and retain patients in clinical trials who more fully reflect real-world populations experiencing the disease or health condition being studied, including U.S. Food and Drug Administration requirements around diversity action plans.
The work reflects Thermo Fisher and NMQF’s share…
The collaboration aims to identify disease-modifying interventions, with the goal of improving standards of care for people living with type 2 diabetes and cardiac fibrosis
The Broad Institute of MIT and Harvard today announced a new research alliance with Novo Nordisk aimed at addressing critical unmet clinical needs in diabetes and cardiometabolic diseases. The collaboration will focus on advancing three programs over the next three years. Two programs aim to identify drug targets for clinically important subtypes of type 2 diabetes, which affects more than 37 million people in the United States alone, and one program aims to unravel the genetic roots of cardiac fibrosis, or scarring of the heart, which occurs in many cardiovascular diseases that can lead to heart dysfunction and failure…
Bigfoot developed Bigfoot Unity, a smart insulin management system that features the first and only FDA-cleared connected insulin pen caps that turn data from a continuous glucose monitor (CGM) into clear and reliable insulin dosing recommendations displayed right on the insulin pen cap
Acquisition will bring together two leaders in different aspects of diabetes care: CGM and insulin injection support
Together, Abbott and Bigfoot will continue to advance technology-driven solutions for making diabetes management even more personal and precise
ABBOTT PARK, Ill. and MILPITAS, Calif., Sept. 5, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) and Bigfoot Biomedical today announced a definitive agreement for Abbott to acquire Bigfoot, a leader in developing smart insulin management systems for people…
Novel non-viral gene delivery platform to help advance tissue repair following orthopaedic surgery
Funding from Innovate UK’s Transforming Medicines Manufacturing programme supporting innovative technologies for intracellular drug delivery
London, UK, and Nottingham, UK, 31 August 2023: TherageniX, a University of Nottingham spin out pioneering a dry powder gene therapy formulation for bone graft augmentation, and its collaborator, the University of Nottingham, have been awarded a £995,000 grant from Innovate UK, the UK’s innovation agency. The funding will support the development of the Company’s gene therapy in a powder, a non-viral gene delivery system to improve tissue regeneration following surgery. TherageniX will initially focus on orthopaedic applications, with the aim of improvi…
Largest single investment in Crop Protection in Germany for 40 years / Focus on Environmental and Human Safety / State-of-the-art lab building and greenhouse / 5 floor main building; 28,000 m2 gross floor area / R&D facility offers space for 200 employees / Early safety screens and A.I. help design the next generation of Crop Protection
Monheim, August 30, 2023 – Bayer significantly strengthens its commitment to innovation in regenerative agriculture with a EUR 220 million investment in research and development (R&D) at its Monheim site. This is the company’s largest single investment in its Crop Protection business in Germany since the founding of the Monheim campus in 1979. The new Product Safety complex with labs, offices, and a greenhouse area offers space for approximately 200…
Powered by Sanofi, a new BioMed X research team will develop a computational platform designed to accelerate drug development.
Heidelberg, June 29, 2023. BioMed X, a German independent research institute, announces the start of its first research project in collaboration with Sanofi: “Next Generation Virtual Patient Engine for Clinical Translation of Drug Candidates” (VPE). The end goal of this research project is to develop a versatile computational platform that can predict the efficacy of first- or best-in-class drug candidates in virtual patient populations at unprecedented accuracy, thereby addressing one of the most critical bottlenecks of the pharmaceutical industry today: a 90% failure rate of new drug candidates during clinical development.
The new research team will be led by D…
Caidya was honored at the CRO Leadership Awards held in Boston, MA at the end of June for their win in the Overall Capabilities category. The award is a recognition of Caidya’s outstanding global capabilities and the tireless work that the team does daily to fulfill our vision to ensure potential therapies have the best opportunity to reach patients in need.
Vice President of Business Development (China), Jinye Shen, attended on behalf of Caidya and expressed her gratitude and excitement for the award in a brief interview with the hosting president, Krishnan Rajugopalan. Key points she raised are:
Caidya operates with an ownership mentality towards clinical research, making our clients’ success a measure of our own success.
As a global company, we help clients navigate regulatory complexi…
Sanofi, Meningitis Research Foundation, and the Confederation of Meningitis Organisations ignite a global awareness initiative against meningitis with launch of The Meningitis Flag
Paris, August 28, 2023. Today, Meningitis Research Foundation, the Confederation of Meningitis Organisations (CoMO) and Sanofi join forces to launch ‘The Meningitis Flag’, a global initiative to raise awareness in the fight against meningitis. With the Paris 2024 Paralympic Games opening in exactly one year, and with the support of para-athletes Ellie Challis (Great Britain), Théo Curin (France), and Davide Morana (Italy), this unique global campaign seeks to increase understanding of a disease that remains one of the world’s largest infectious disease killers, and yet is largely preventable.1,2
Despite major pr…
NEW BRUNSWICK, N.J., August 23, 2023 – Johnson & Johnson (NYSE: JNJ) today announced the final results of its previously announced offer to its shareholders to exchange their shares of Johnson & Johnson common stock for shares of Kenvue Inc. (NYSE: KVUE) (“Kenvue”) common stock owned by Johnson & Johnson. The exchange offer expired at 12:00 midnight, New York City time, at the end of the day on August 18, 2023.
Pursuant to the exchange offer, Johnson & Johnson has accepted 190,955,436 shares of Johnson & Johnson common stock in exchange for 1,533,830,450 shares of Kenvue common stock.
Because the exchange offer was oversubscribed, Johnson & Johnson accepted only a portion of the shares of its common stock that were validly tendered and not validly withdrawn, on a pr…
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today published its 2022 Environmental, Social, and Governance (ESG) Report, which details the Company’s goals, strategies, and performance across its four ESG focus areas including ethics, integrity, and quality; health equity and access to healthcare; global inclusion and diversity; and environmental sustainability.
As a leading biopharmaceutical company, Bristol Myers Squibb is committed to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. The Company’s ESG strategy is embedded in its mission and builds on a legacy of comprehensive and global sustainability efforts that seek to drive business value and positively impact patients, employees, communities, and th…
23 August 2023: Kadans Science Partner (“Kadans”) is set to welcome AviadoBio to its recently completed wet lab innovation and flexible workspace centre at 20 Water Street in Canary Wharf.
AviadoBio, a pioneering gene therapy company developing and delivering transformative medicines for neurodegenerative disorders, will establish laboratory and office presence at the Innovation Centre.
AviadoBio will begin working at Kadans’ London Innovation Centre following the recent completion of their wet-lab Innovation Centre at levels four and five at 20 Water Street. The company will be joining the Kadans’ growing European ecosystem of over 450 tenants including Cytiva, Akamis Bio, GeneFirst and Sherlock Bioscience.
Lisa Deschamps, CEO of AviadoBio, said: “We are very excited about our new partner…
